IBDV strain in ovo administration

• US 6,451,321 B1
• Filed: 06/08/2001
• Issued: 09/17/2002
• Est. Priority Date: 06/09/2000
• Status: Expired due to Fees

• Current Assignee: Akzo Nobel N.V. (Nouryon BV)
• Original Assignee: Akzo Nobel N.V. (Nouryon BV)
• Inventors: Mundt, Egbert, Loon Van, Adriaan Antonius Wilhelmus Maria
• Primary Examiner(s): Mosher, Mary E.
• Assistant Examiner(s): Hill, Myron G.
• Application Number:
  US09/878,083
• Time in Patent Office: 466 Days
• Field of Search: 424/204.1, 424/184.1, 424/205.1, 424/209.1, 424/214.1, 424/201.1, 424/202.1, 424/215.1, 435/235.1, 435/236
• US Class Current: 424/204.1
• CPC Class Codes: A61K 2039/55 characterised by the host/recipient, e.g. newborn with maternal antibodies
• CPC Class Codes: A61K 2039/552 Veterinary vaccine
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C12N 2720/10021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
• CPC Class Codes: C12N 2720/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention provides a novel infectious bursal disease virus, strain 689 which is suited as vaccine candidate for in ovo vaccination and is deposited at the European Collection of Cell Cultures, Salisbury, Wiltshine, United Kingdom under No. V00012609.

Claims

1. A virus which is infectious bursal disease virus strain 689, which does not cause severe lesions in the bursa of Fabricius after in ovo administration and is deposited at the European Collection of Cell Cultures, Salisbury, Wiltshire, SP4 OJG, United Kingdom under accession No. V00012609.

2. A method for the propagating of the virus according to claim 1, comprising culturing the virus on a suitable substrate and harvesting the virus from the substrate.

3. A vaccine against infectious bursal disease, comprising a virus according to claim 1 and a pharmaceutically acceptable carrier or a diluent.

4. The vaccine according to claim 3, comprising an effective dose of 10¹-10⁶ TCID₅₀, (Tissue Culture Effective Dose 50).

5. The vaccine according to claim 4, comprising a dose per egg of 10²-10⁵ TCID₅₀.

6. The vaccine according to claim 3, which additionally comprises an embryo-safe vaccine strain of another avian pathogen.

7. A method for protecting a bird against infectious bursal disease, comprising administering an effective amount of the vaccine according to claim 3.

8. The method of claim 7, wherein the vaccine in administered to an embryo.

9. The method of claim 8, wherein the vaccine is administered in the amount of 10¹-10⁶ TCID₅₀.

10. The method of claim 9, wherein the vaccine is administered in the amount of 10²-10⁵ TCID₅₀.